Pure red cell aplasia after <scp>ABO</scp> incompatible allogeneic stem cell transplantation treated with therapeutic plasma exchange: A case report

Pure red cell aplasia (PRCA) is a known complication of major/bi-directional ABO incompatible allogeneic stem cell transplantation (ABOi allo-SCT). Persistence of recipient's antibodies against the donor's red blood cells (RBCs) leads to delay in recovery of RBCs which can last up to several months. This complication can result in patients becoming transfusion dependent. There is no standard treatment but a combination of different treatment strategies which includes tapering immunosuppression/discontinuation, steroid, erythropoietin, anti-CD-20 monoclonal antibody, daratumumab and therapeutic plasma exchange (TPE). Here we report a case of PRCA after ABOi allogeneic peripheral blood SCT treated successfully with TPE.